TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Life-Stress Interview for Women With Chronic Urogenital Pain Conditions
Brief Summary: The goal of this study is to test the efficacy, feasibility, and acceptability of providing an experiential assessment interview that targets health, and emotional and stressful experiences in a tertiary care setting specializing in women's urology.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
B: Arm Label: Botulinum toxin A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A | Arm Label: Control arm-Normal saline instillation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline instillation | Intervention Type: DRUG; Name: Botulinum toxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: DRUG; Name: Normal saline instillation; Assigned to Arm(s): Control arm-Normal saline instillation
C: Arm Label: Bladder instillation WITH triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder instillation WITH triamcinolone acetonide | Arm Label: Bladder instillation WITHOUT triamcinolone acetonide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bladder instillation WITHOUT triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITH triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITH triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITHOUT triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITHOUT triamcinolone acetonide
D: Arm Label: Life-Stress Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Life-Stress Interview | Arm Label: Wait-list Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Life-Stress Interview; Assigned to Arm(s): Life-Stress Interview

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Patient-Centered Risk Stratification Method for Improving Primary Care for Back Pain
Brief Summary: Back pain is one of the most common, controversial and costly problems in healthcare. Despite numerous studies, care for back pain has deteriorated over time and become much more expensive. The risk stratification approach developed in England and found effective in National Health Service general practices in the UK provides a very promising strategy for improving care for back pain in the U.S.

The MATCH trial will use a cluster randomization design involving 6 primary care clinics at Group Health. Of these 6 clinics, 3 will be randomized to receive Group Health's standard training in the use of Group Health back pain guidelines and 3 clinics will receive this standard training plus supplemental training. Primary care clinicians and physical therapists in the intervention group will receive training in the use of the STarTBack risk stratification strategy for matching the most appropriate evidence-based treatments to the needs of patients in each risk level. We will evaluate the effect of this supplemental training on patient outcomes, clinician and physical therapist knowledge and comfort treating patients with back pain, and utilization of services for back pain.


Options:
A: Arm Label: Intervention; Type: N/A; Interventions: N/A | Arm Label: Control; Type: N/A; Interventions: N/A
B: Arm Label: PRO-based follow-up; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based follow-up | Arm Label: PRO-based telephone consultations; Type: EXPERIMENTAL; Interventions: Behavioral: PRO-based telephone consultation | Arm Label: Usual outpatient follow-up visits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PRO-based follow-up; Assigned to Arm(s): PRO-based follow-up | Intervention Type: BEHAVIORAL; Name: PRO-based telephone consultation; Assigned to Arm(s): PRO-based telephone consultations
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: THRIVE App; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVE App | Arm Label: THRIVE App+Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVE App, Behavioral: Tailored Feedback Messages | Intervention Type: BEHAVIORAL; Name: THRIVE App; Assigned to Arm(s): THRIVE App, THRIVE App+Feedback | Intervention Type: BEHAVIORAL; Name: Tailored Feedback Messages; Assigned to Arm(s): THRIVE App+Feedback
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: AEP score available to the treating physician | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: AEP score available to the treating physician; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial
Brief Summary: Educational research study where goal is to test educational materials that help people make informed decisions about lung cancer screening.


Options:
A: Arm Label: Patient Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient Decision Aid, Behavioral: Follow-Up Assessments: Questionnaires | Arm Label: Standard Educational Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Educational Information, Behavioral: Follow-Up Assessments: Questionnaires | Intervention Type: BEHAVIORAL; Name: Patient Decision Aid; Assigned to Arm(s): Patient Decision Aid | Intervention Type: BEHAVIORAL; Name: Standard Educational Information; Assigned to Arm(s): Standard Educational Information | Intervention Type: BEHAVIORAL; Name: Follow-Up Assessments: Questionnaires; Assigned to Arm(s): Patient Decision Aid, Standard Educational Information
B: Arm Label: Structured patient visits; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Arm Label: Treatment as usual; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Intervention Type: BEHAVIORAL; Name: Structured patient-centered follow up of depression; Assigned to Arm(s): Structured patient visits, Treatment as usual
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Loop | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Loop; Assigned to Arm(s): Intervention Group
D: Arm Label: Interventional arm; Type: EXPERIMENTAL; Interventions: Other: Routine Assessment of HRQoL coupled with Therapeutic Information | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Routine Assessment of HRQoL coupled with Therapeutic Information; Assigned to Arm(s): Interventional arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali
Brief Summary: This study is an evaluation of the immune response to pentavalent rotavirus vaccine (PRV) after an additional fourth dose is given at 9 months of age with local World Health Organization (WHO) Expanded Programme on Immunization (EPI) vaccines in Mali.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Arm Label: Group A (without rotavirus vaccine); Type: ACTIVE_COMPARATOR; Interventions: Biological: measles vaccine (MV), Biological: yellow fever vaccine (YFV), Biological: meningitis conjugate vaccine (PsA-TT-5μg) | Arm Label: Group B (with rotavirus vaccine); Type: EXPERIMENTAL; Interventions: Biological: pentavalent rotavirus vaccine (PRV), Biological: measles vaccine (MV), Biological: yellow fever vaccine (YFV), Biological: meningitis conjugate vaccine (PsA-TT-5μg) | Intervention Type: BIOLOGICAL; Name: pentavalent rotavirus vaccine (PRV); Assigned to Arm(s): Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: measles vaccine (MV); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: yellow fever vaccine (YFV); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine) | Intervention Type: BIOLOGICAL; Name: meningitis conjugate vaccine (PsA-TT-5μg); Assigned to Arm(s): Group A (without rotavirus vaccine), Group B (with rotavirus vaccine)
C: Arm Label: Rotavin; Type: EXPERIMENTAL; Interventions: Drug: Rotavin | Intervention Type: DRUG; Name: Rotavin; Assigned to Arm(s): Rotavin
D: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Brief Summary: Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.


Options:
A: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo
B: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
C: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin
D: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Brief Summary: Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.


Options:
A: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo
B: Arm Label: Plasma and Standard Care; Type: EXPERIMENTAL; Interventions: Biological: Anti-Influenza Immune Plasma, Drug: Standard Care | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Care | Intervention Type: BIOLOGICAL; Name: Anti-Influenza Immune Plasma; Assigned to Arm(s): Plasma and Standard Care | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): Plasma and Standard Care, Standard Care
C: Arm Label: Convalescent plasma group; Type: EXPERIMENTAL; Interventions: Biological: Convalescent plasma, Drug: Hydroxychloroquin with Azithromycin | Arm Label: Control group; Type: OTHER; Interventions: Drug: Hydroxychloroquin with Azithromycin | Intervention Type: BIOLOGICAL; Name: Convalescent plasma; Assigned to Arm(s): Convalescent plasma group | Intervention Type: DRUG; Name: Hydroxychloroquin with Azithromycin; Assigned to Arm(s): Control group, Convalescent plasma group
D: Arm Label: Plasma; Type: EXPERIMENTAL; Interventions: Biological: Convalescent Plasma | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Convalescent Plasma; Assigned to Arm(s): Plasma | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
Brief Summary: Influenza (the flu) is a common illness that usually occurs in autumn and winter. The flu is usually mild, but can cause serious illness or death. The purpose of this study is to test the safety and effectiveness of an antibody against the flu (called intravenous hyperimmune immunoglobulin or IVIG) in people who are hospitalized for severe flu.


Options:
A: Arm Label: treated; Type: EXPERIMENTAL; Interventions: Other: hyperimmune plasma | Intervention Type: OTHER; Name: hyperimmune plasma; Assigned to Arm(s): treated
B: Intervention Type: BIOLOGICAL; Name: COVID-19 convalescent plasma; Assigned to Arm(s): N/A
C: Arm Label: Intravenous immunoglobulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous immunoglobulin | Arm Label: Hyperimmune intravenous immunoglobulin; Type: EXPERIMENTAL; Interventions: Drug: Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Hyperimmune intravenous immunoglobulin; Assigned to Arm(s): Hyperimmune intravenous immunoglobulin | Intervention Type: DRUG; Name: Intravenous immunoglobulin; Assigned to Arm(s): Intravenous immunoglobulin
D: Arm Label: Arm A: hIVIG; Type: EXPERIMENTAL; Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG) | Arm Label: Arm B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo for IVIG | Intervention Type: BIOLOGICAL; Name: Intravenous hyperimmune immunoglobulin (IVIG); Assigned to Arm(s): Arm A: hIVIG | Intervention Type: BIOLOGICAL; Name: Placebo for IVIG; Assigned to Arm(s): Arm B: Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen
Brief Summary: The aim of the TELESAGE study is to demonstrate

1. the superiority of follow up with the DIABEO system (software alone) versus usual follow up in terms of improvement in HbA1c after 1 year in DM1 or DM2 patients treated with a basal-bolus insulin regimen.
2. the superiority of follow up with the DIABEO system (software + telemonitoring) compared to usual follow up in terms of improvement in HbA1c after 1 year in DM1 or DM2 patients treated with a basal-bolus insulin regimen.

The DIABEO software alone is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system.

The DIABEO software added by paramedical telemonitoring is the electronic diary combined with remote paramedical monitoring of data (telemeonitoring)


Options:
A: Arm Label: eConsult; Type: EXPERIMENTAL; Interventions: Other: Champlain BASE eConsult Service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Champlain BASE eConsult Service; Assigned to Arm(s): eConsult
B: Arm Label: DIABEO software alone; Type: EXPERIMENTAL; Interventions: Device: DIABEO software | Arm Label: DIABEO+paramedical telemonitoring; Type: EXPERIMENTAL; Interventions: Device: DIABEO software | Arm Label: Usual Follow up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: DIABEO software; Assigned to Arm(s): DIABEO software alone, DIABEO+paramedical telemonitoring
C: Arm Label: Experimental; Type: N/A; Interventions: Other: CAPRI | Arm Label: Control; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: CAPRI; Assigned to Arm(s): Experimental
D: Arm Label: Usual care (UC); Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Device: Self-management | Arm Label: PCTM intervention; Type: EXPERIMENTAL; Interventions: Other: PCTM intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care (UC) | Intervention Type: DEVICE; Name: Self-management; Assigned to Arm(s): Self-management | Intervention Type: OTHER; Name: PCTM intervention; Assigned to Arm(s): PCTM intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Effectiveness and Cost-effectiveness of a Fall Prevention Intervention: Tai Ji Quan: Moving for Better Balance
Brief Summary: Objective: To conduct a comparative efficacy and cost-effectiveness study of an evidence-based fall prevention program-Tai Ji Quan: Moving for Better Balance (TJQMBB).


Options:
A: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
B: Arm Label: Tai Ji Quan: Moving for Better Balance; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Ji Quan: Moving for Better Balance | Arm Label: Multimodal Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multimodal Exercise | Arm Label: Stretching; Type: SHAM_COMPARATOR; Interventions: Behavioral: Stretching | Intervention Type: BEHAVIORAL; Name: Tai Ji Quan: Moving for Better Balance; Assigned to Arm(s): Tai Ji Quan: Moving for Better Balance | Intervention Type: BEHAVIORAL; Name: Multimodal Exercise; Assigned to Arm(s): Multimodal Exercise | Intervention Type: BEHAVIORAL; Name: Stretching; Assigned to Arm(s): Stretching
C: Intervention Type: PROCEDURE; Name: Falls Prevention Program; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Intervention Type: BEHAVIORAL; Name: Exercise Training; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean
Brief Summary: The investigators propose a prospective, randomized trial evaluating the use of negative pressure wound therapy (NPWT) with high risk obstetrical patients. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators aim to look at all wound complications such as infection and disruption and will be using Prevena incision management system for our NPWT device .


Options:
A: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection
B: Arm Label: Prevena device (Group A); Type: EXPERIMENTAL; Interventions: Device: Prevena device (Group A) | Arm Label: Conventional dressing (Group B); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Prevena device (Group A); Assigned to Arm(s): Prevena device (Group A)
C: Arm Label: Dry Dressing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: V.A.C. by K.C.I. | Intervention Type: DEVICE; Name: V.A.C. by K.C.I.; Assigned to Arm(s): Negative Pressure Wound Therapy
D: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy

Answer: D